Preserving mTOR Oscillatory Amplitude, Not Just Its Mean Level, sustains circadian coupling of growth and autophagy to extend healthspan
Hypothesis
We propose that the health benefits of mTOR modulation depend on preserving the oscillatory amplitude of its activity rather than merely lowering its average level. Chronic suppression flattens the signal, decoupling anabolic and catabolic programs from circadian timing, which accelerates age‑related decline. Maintaining rhythmic mTOR swings sustains temporal gating of autophagy and protein synthesis, thereby supporting cellular civilization without sacrificing survival capacity.
Mechanistic Basis
mTORC1 drives translation of core clock components such as BMAL1 and REV‑ERBα (see 1). When mTOR activity rises, it promotes synthesis of BMAL1, enhancing transcription of circadian‑regulated genes that govern metabolism and growth. Conversely, mTOR troughs relieve inhibition of the ULK1 complex, permitting autophagosome formation. This push‑pull creates a gate where anabolic processes peak during the active phase and cleanup peaks during the rest phase. If the amplitude is dampened—by constant rapamycin or constitutive activation—these gates blur, leading to mistimed protein synthesis and incomplete clearance of damaged organelles. Over time, mistimed anabolism fuels accrual of dysfunctional proteins, while blunted autophagy permits accumulation of senescent markers, reproducing the pathological states described in chronic mTOR inhibition (3) and hyperactivation (2).
Testable Predictions
- Mice receiving timed rapamycin pulses aligned with the onset of the active phase will show higher mTORC1 activity amplitude (measured by phospho‑S6K) than mice receiving continuous rapamycin, despite comparable average inhibition.
- Preserved amplitude will correlate with stronger circadian oscillation of autophagy markers (LC3‑II, p62) and clock‑gene expression (Bmal1, Rev‑erbα).
- Consequently, pulsed‑rapamycin animals will exhibit improved muscle contractile force, better glucose tolerance, and lower senescence‑associated β‑galactosidase staining compared with continuous‑rapamycin or untreated controls, even if mean mTOR inhibition is identical.
Experimental Design
- Use male C57BL/6 mice, 6 months old.
- Three groups (n=12 each): (A) vehicle control, (B) continuous rapamycin (2 mg/kg/day via chow), (C) pulsed rapamycin (same total weekly dose delivered as six‑hour pulses at ZT0, three times weekly).
- Monitor food intake and body weight weekly.
- After 8 weeks, collect liver and gastrocnemius muscle every 4 h over 24 h.
- Western blot for phospho‑S6K (mTORC1 readout), total S6K, LC3‑II, p62, BMAL1, REV‑ERBα.
- qPCR for clock genes.
- Assess muscle grip strength, glucose tolerance test, and SA‑β‑gal staining.
- Statistical analysis: two‑way ANOVA (treatment × time) for rhythmicity metrics; post‑hoc tests for amplitude and phase.
Potential Implications
If pulsed mTOR inhibition preserves signaling amplitude and improves healthspan, it would reframe longevity strategies from static suppression to dynamic timing. This approach could retain the organism’s capacity for tissue repair and growth while still engaging survival pathways, addressing the trade‑off highlighted by chronic rapamycin‑induced insulin resistance (3). Translating to humans might involve timed dosing of rapalogs or dietary regimens that create natural mTOR waves (e.g., intermittent fasting aligned with circadian peaks), offering a route to delay aging without sacrificing the "civilizational" functions of cells.